← Back to Screener
Nutriband Inc. Common Stock (NTRB)
Price$3.58
Value ScoreF
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-35.53%
Price vs S&P 500 (4W)-4.52%
VGM Score26.88
Market Capitalization$43.52M
All Metrics
Book Value / Share (Quarterly)$0.55
P/TBV (Annual)8.81x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-0.69%
Cash Flow / Share (Quarterly)$-0.42
Price vs S&P 500 (YTD)-29.30%
Gross Margin (TTM)27.81%
Net Profit Margin (TTM)-404.08%
EPS (TTM)$-0.70
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-0.70
Revenue Growth (5Y)16.63%
EPS (Annual)$-0.71
ROI (Annual)-120.24%
Gross Margin (Annual)27.81%
Net Profit Margin (5Y Avg)-361.39%
Cash / Share (Quarterly)$0.38
Revenue Growth QoQ (YoY)-37.62%
ROA (Last FY)-109.03%
Revenue Growth TTM (YoY)-4.81%
EBITD / Share (TTM)$-0.70
ROE (5Y Avg)-95.17%
Operating Margin (TTM)-408.41%
Cash Flow / Share (Annual)$-0.42
P/B Ratio6.52x
P/B Ratio (Quarterly)8.55x
Net Income / Employee (Annual)$-633,000
EV / Revenue (TTM)19.20x
Net Interest Coverage (TTM)-92.02x
ROA (TTM)-101.93%
EPS Incl Extra (Annual)$-0.71
Current Ratio (Annual)6.36x
Quick Ratio (Quarterly)5.98x
3-Month Avg Trading Volume0.01M
52-Week Price Return-50.69%
Revenue / Employee (TTM)$156,700
Tangible BV / Share (Quarterly)$0.53
P/S Ratio (Annual)21.37x
Asset Turnover (Annual)0.27x
52-Week High$11.68
Operating Margin (5Y Avg)-361.54%
EPS Excl Extra (Annual)$-0.71
Tangible BV CAGR (5Y)1.20%
26-Week Price Return-27.60%
Quick Ratio (Annual)5.98x
13-Week Price Return-15.57%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)6.36x
Enterprise Value$39.11M
Revenue / Share Growth (5Y)4.53%
Asset Turnover (TTM)0.25x
Book Value / Share Growth (5Y)-10.82%
Revenue / Employee (Annual)$156,700
Inventory Turnover (Annual)8.91x
Pretax Margin (Annual)-404.08%
Cash / Share (Annual)$0.38
3-Month Return Std Dev53.92%
Gross Margin (5Y Avg)35.09%
Net Income / Employee (TTM)$-633,000
ROE (Last FY)-123.21%
Net Interest Coverage (Annual)-89.73x
EPS Basic Excl Extra (Annual)$-0.71
Receivables Turnover (TTM)21.19x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.70
Receivables Turnover (Annual)21.19x
ROI (TTM)-115.43%
P/S Ratio (TTM)21.37x
Pretax Margin (5Y Avg)-361.39%
Revenue / Share (Annual)$0.17
Tangible BV / Share (Annual)$0.53
Forward P/E2.28x
Price vs S&P 500 (52W)-75.05%
Year-to-Date Return-21.15%
5-Day Price Return0.85%
EPS Normalized (Annual)$-0.71
ROA (5Y Avg)-83.64%
Net Profit Margin (Annual)-404.08%
Month-to-Date Return2.58%
Cash Flow / Share (TTM)$-0.55
EBITD / Share (Annual)$-0.70
Operating Margin (Annual)-408.41%
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-92.88%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-0.70
P/TBV (Quarterly)8.81x
P/B Ratio (Annual)8.55x
Inventory Turnover (TTM)8.91x
Pretax Margin (TTM)-404.08%
Book Value / Share (Annual)$0.55
Price vs S&P 500 (13W)-23.82%
Beta1.93x
Revenue / Share (TTM)$0.17
ROE (TTM)-118.30%
52-Week Low$3.21
vGradeF
gGradeD
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q4 26-0.08est. -1.93
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Orthopedic & Prosthetic Devices(33)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NTRBNutriband Inc. Common Stock | F | D | D | $3.58 |
| ISRGIntuitive Surgical Inc. | F | B | C | $422.06 |
| EWEdwards Lifesciences Corp | D | C | C | $85.96 |
| STESTERIS plc | C | B | C | $212.35 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | C | $87.33 |
| ALGNAlign Technology Inc | B | C | C | $167.74 |
| SNNSmith & Nephew plc | B | C | C | $30.61 |
| MSAMine Safety Incorporated | B | C | C | $161.30 |
| ESTAEstablishment Labs Holdings Inc. | F | A | B | $74.31 |
| ENOVEnovis Corporation | B | D | C | $23.78 |
| CDRECadre Holdings, Inc. | C | C | D | $30.01 |
About
Nutriband Inc develops transdermal pharmaceutical products designed to prevent drug abuse and diversion. The company's proprietary AVERSA technology incorporates aversive agents into pharmaceutical formulations to reduce the risk of opioid abuse and misuse. Revenue is generated through the sale of consumer transdermal and coated pharmaceutical products.